Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Atrial septal defect (ASD) with severe pulmonary arterial hypertension (PAH) is thought to preclude shunt closure. However,there are several reports that vasodilator treatment is associated with good clinical outcome in these patients, recently. We report a case of good clinical outcome in a patient with ASD and severe PAH successfully treated with operative closure of ASD and subsequent use of oral bosentan medication. This case supports that the corrective repair of ASD and an oral bosentan treatment can be one of the treatment options in the selected patients with severe PAH associated with ASD.
Abstract
Atrial septal defect (ASD) with severe pulmonary arterial hypertension (PAH) is thought to preclude shunt closure. However,there are several reports that vasodilator treatment is associated with good clinical outcome in these patients, recently. We report a case of good clinical outcome in a patient with ASD and severe PAH successfully treated with operative closure of ASD and subsequent use of oral bosentan medication. This case supports that the corrective repair of ASD and an oral bosentan treatment can be one of the treatment options in the selected patients with severe PAH associated with ASD.
참고문헌 (11)
- Steele PM, "Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction", Circulation, 76, pp.1037~1042 (1987)
- Murphy JG, "Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years", N Engl J Med, 323, pp.1645~1650 (1990)
- Kim YH, "Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy", Ann Thorac Surg, 89, pp.1629~1630 (2010)
- Schwerzmann M, "Atrial septal defect closure in a patient with “irreversible” pulmonary hypertensive arteriopathy", Int J Cardiol, 110, pp.104~107 (2006)
- Sachweh JS, "Hypertensive pulmonary vascular disease in adults with secundum or sinus venosus atrial septal defect", Ann Thorac Surg, 81, pp.207~213 (2006)
- Cherian G, "Pulmonary hypertension in isolated secundum atrial septal defect: high frequency in young patients", Am Heart J, 105, pp.952~957 (1983)
- Craig RJ, "Natural history and prognosis of atrial septal defect", Circulation, 37, pp.805~815 (1968)
- Balint OH, "Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure", Heart, 94, pp.1189~1193 (2008)
- Yamauchi H, "Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect", Ann Thorac Surg, 72, pp.905~906 (2001)
- Galiè N, "Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study", Circulation, 114, pp.48~54 (2006)
- Yamaki S, "Secundum atrial septal defect with severe pulmonary hypertension. Open lung biopsy diagnosis of operative indication", Chest, 91, pp.33~38 (1987)